1. Home
  2. INKT vs RNXT Comparison

INKT vs RNXT Comparison

Compare INKT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INKT
  • RNXT
  • Stock Information
  • Founded
  • INKT 2017
  • RNXT 2012
  • Country
  • INKT United States
  • RNXT United States
  • Employees
  • INKT N/A
  • RNXT N/A
  • Industry
  • INKT Medicinal Chemicals and Botanical Products
  • RNXT Biotechnology: Pharmaceutical Preparations
  • Sector
  • INKT Health Care
  • RNXT Health Care
  • Exchange
  • INKT Nasdaq
  • RNXT Nasdaq
  • Market Cap
  • INKT 48.7M
  • RNXT 44.6M
  • IPO Year
  • INKT 2021
  • RNXT 2021
  • Fundamental
  • Price
  • INKT $15.83
  • RNXT $1.16
  • Analyst Decision
  • INKT Buy
  • RNXT Strong Buy
  • Analyst Count
  • INKT 3
  • RNXT 2
  • Target Price
  • INKT $37.50
  • RNXT $7.50
  • AVG Volume (30 Days)
  • INKT 87.6K
  • RNXT 420.2K
  • Earning Date
  • INKT 08-14-2025
  • RNXT 08-14-2025
  • Dividend Yield
  • INKT N/A
  • RNXT N/A
  • EPS Growth
  • INKT N/A
  • RNXT N/A
  • EPS
  • INKT N/A
  • RNXT N/A
  • Revenue
  • INKT N/A
  • RNXT $662,000.00
  • Revenue This Year
  • INKT N/A
  • RNXT $2,988.37
  • Revenue Next Year
  • INKT N/A
  • RNXT $300.60
  • P/E Ratio
  • INKT N/A
  • RNXT N/A
  • Revenue Growth
  • INKT N/A
  • RNXT N/A
  • 52 Week Low
  • INKT $4.56
  • RNXT $0.75
  • 52 Week High
  • INKT $76.00
  • RNXT $1.69
  • Technical
  • Relative Strength Index (RSI)
  • INKT 53.11
  • RNXT 54.99
  • Support Level
  • INKT $13.11
  • RNXT $0.90
  • Resistance Level
  • INKT $15.26
  • RNXT $1.26
  • Average True Range (ATR)
  • INKT 1.23
  • RNXT 0.08
  • MACD
  • INKT 0.08
  • RNXT 0.04
  • Stochastic Oscillator
  • INKT 85.26
  • RNXT 80.43

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Share on Social Networks: